Fdc

Sector: Biotechnology & Drugs
265.00 -0.60 (-0.23%)
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y

Price Range

Today’s Low 261.0
Today’s High 269.5
52 Week Low 229.15
52 Week High 372.7

Key Metrics

  • Market Cap (In Cr) 4401.59
  • Beta 0.63
  • Div. Yield (%) 0
  • P/B 2.29
  • TTM P/E 21.23
  • Peg Ratio 0.28
  • Sector P/E 31.98
  • D/E -1000
  • Open Price 269.5
  • Prev Close 265.6

Analysis

Price Analysis
  • 1 Week
    4.1%
  • 3 Months
    8.31%
  • 6 Month
    -11.61%
  • YTD
    -12.79%
  • 1 Year
    -23.86%
Risk Meter
  • 30% Low risk
  • 30% Moderate risk
  • 30% Balanced Risk
  • 30% High risk
  • 30% Extreme risk
Recos
1 Analysts
  • Strong Sell
  • Sell
  • Hold
  • Buy
  • Strong Buy
Analysts' Views
  • Ratings
  • Current
  • Strong Sell
  • 0
  • Sell
  • 0
  • Hold
  • 0
  • Buy
  • 0
  • Strong Buy
  • 1

Financials

  • INCOME
  • BALANCE SHEET
  • Cashflow
  • Period
  • 2022
  • Total Revenue
  • 1527.92
  • Selling/ General/ Admin Expenses Total
  • 343.33
  • Depreciation/ Amortization
  • 37.3
  • Other Operating Expenses Total
  • 400.69
  • Total Operating Expense
  • 1311.53
  • Operating Income
  • 216.38
  • Net Income Before Taxes
  • 289.39
  • Net Income
  • 216.4
  • Diluted Normalized EPS
  • 12.81
  • Period
  • 2021
  • Total Revenue
  • 1333.2
  • Selling/ General/ Admin Expenses Total
  • 486.56
  • Depreciation/ Amortization
  • 37.81
  • Other Operating Expenses Total
  • 31.42
  • Total Operating Expense
  • 1039.09
  • Operating Income
  • 294.12
  • Net Income Before Taxes
  • 387.73
  • Net Income
  • 301.35
  • Diluted Normalized EPS
  • 17.79
  • Period
  • 2020
  • Total Revenue
  • 1344.19
  • Selling/ General/ Admin Expenses Total
  • 509.35
  • Depreciation/ Amortization
  • 37.46
  • Other Operating Expenses Total
  • 38.99
  • Total Operating Expense
  • 1063.77
  • Operating Income
  • 280.43
  • Net Income Before Taxes
  • 320.97
  • Net Income
  • 239.88
  • Diluted Normalized EPS
  • 13.17
  • Period
  • 2019
  • Total Revenue
  • 1090.7
  • Selling/ General/ Admin Expenses Total
  • 422.28
  • Depreciation/ Amortization
  • 33.24
  • Other Operating Expenses Total
  • 42.47
  • Total Operating Expense
  • 894.04
  • Operating Income
  • 196.66
  • Net Income Before Taxes
  • 236.64
  • Net Income
  • 169.79
  • Diluted Normalized EPS
  • 9.77
  • Period
  • 2018
  • Total Revenue
  • 1083.09
  • Selling/ General/ Admin Expenses Total
  • 403.71
  • Depreciation/ Amortization
  • 35.14
  • Other Operating Expenses Total
  • 36.92
  • Total Operating Expense
  • 885.19
  • Operating Income
  • 197.9
  • Net Income Before Taxes
  • 240.63
  • Net Income
  • 173.51
  • Diluted Normalized EPS
  • 9.73
  • Period
  • 2017
  • Total Revenue
  • 1050.98
  • Selling/ General/ Admin Expenses Total
  • 342.02
  • Depreciation/ Amortization
  • 34.62
  • Other Operating Expenses Total
  • 49.05
  • Total Operating Expense
  • 848.02
  • Operating Income
  • 202.96
  • Net Income Before Taxes
  • 251.83
  • Net Income
  • 188.53
  • Diluted Normalized EPS
  • 10.85

Forecast

Income Sheet (In Cr) Net Income Vs Revenue
Returns Metrics (In Cr) ROA Vs ROE

Technical

Moving Average SMA
  • 5 Day268.39
  • 10 Day261.39
  • 20 Day258.77
  • 50 Day248.32
  • 100 Day255.63
  • 300 Day276.09

Peers

  • Price
  • Ratio
  • Name
  • Latest Price
  • Change
  • % Change
  • 52W High
  • 52W Low
  • Mkt. Cap
  • Jubilant Pharmova
  • 354.1
  • 0.75
  • 0.21
  • 690
  • 317.65
  • 5624.41
  • Glenmark Life Sciences
  • 437.25
  • -3.1
  • -0.7
  • 774.7
  • 376
  • 5395.48
  • FDC
  • 265
  • -0.6
  • -0.23
  • 372.7
  • 229.15
  • 4401.59
  • Aarti Drugs
  • 428.75
  • 1.85
  • 0.43
  • 669.4
  • 378.4
  • 3960.04
  • Shilpa Medicare
  • 397.3
  • -15.2
  • -3.68
  • 657.95
  • 380.35
  • 3587.52

Corporate Actions

  • Board Meeting
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
  • Meeting Date
  • Purpose
  • 04-Aug-22
  • Quarterly Results
  • 25-May-22
  • Audited & Quarterly Results
  • 09-Feb-22
  • Quarterly Results
  • 11-Nov-21
  • Quarterly Results
  • 12-Aug-21
  • Quarterly Results
  • 26-May-21
  • Audited Results
  • 04-Feb-21
  • Quarterly Results

Company Profile

ABOUT FDC

  • Industry Biotechnology & Drugs
  • ISIN INE258B01022
  • BSE Code 531599
  • NSE Code FDC

FDC Limited is an India-based company, which is principally engaged in the business of pharmaceuticals. The Company manufactures and distributes its range of generics, formulations and active pharmaceuticals at its manufacturing plants. It also manufactures oral rehydration salts (ORS) and specialized formulations. It has a range of functional foods and beverages. Its active pharmaceutical ingredients (APIs) include Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen, Flurbiprofen Sodium, Miconazole Nitrate and Timolol Maleate, among others. It has its presence in various therapeutic segments, such as anti-infectives, gastrointestinal, ophthalmological, vitamins/ minerals/ dietary supplements, cardiac, anti-diabetes, respiratory, gynecology, dermatology, analgesics and others. Its various brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.

MANAGEMENT

  • Mohan Chandavarkar Executive Chairman of the Board, Managing Director
  • Varsharani Katre Compliance Officer, Company Secretary
  • Nandan Chandavarkar Joint Managing Director, Executive Director
  • Ameya Chandavarkar Executive Director
  • Ashok Chandavarkar Executive Director
  • Nomita Chandavarkar Whole-Time Director

Recommended For You

×
Edit Profile
Get alerts on WhatsApp
Set Preferences My ReadsWatchlistFeedbackRedeem a Gift CardLogout